JDRF Blog

Latest in Glucose control

  • JDRF Clinical Trial Results Announced at the 55th EASD Meeting

    September 18, 2019

    A protein, called glucokinase (or GK), acts as a key regulator of sugar levels in the body. If blood glucose levels are...

  • FDA Approves Xeris Pharmaceuticals’ Glucagon to Treat Severe Hypoglycemia

    September 11, 2019

    “The approval of the GVOKE HypoPenTM is an important step forward for people with diabetes. Severe hypoglycemia is a terrifying and dangerous...

  • FDA Approves the First Low Blood Sugar Treatment WITHOUT an Injection

    July 25, 2019

    Type 1 diabetes (T1D) can bring the fear of developing low blood sugar, called hypoglycemia, which can arise if someone takes too...

  • Proof-of-Concept for Hypoglycemia Prevention

    June 5, 2019

    Hypoglycemia, or low blood sugar, can have serious effects, and it is, for most people with type 1 diabetes (T1D), the most...

  • Can a Snail Hold the Key to Better Blood Sugar Control?

    February 26, 2019

    “Rapid-acting” insulin analogs were introduced commercially in the 1990s; however, these insulins are still slower than insulin secreted from a nondiabetic pancreas,...

  • SGLT Inhibition: It’s Not Just for Type 2 Anymore

    February 8, 2019

    SGLT inhibition may soon be approved for use for people with type 1 diabetes Can a drug long-used for type 2 diabetes,...

  • Maybe it’ll Work for Type 1: Clinical Trial Results Announced

    February 1, 2019

    A protein, called glucokinase (or GK), acts as a key regulator of sugar levels in the body, and its expression is limited to tissues that require sugar-sensing, mainly the liver and pancreatic beta cells. If blood glucose levels are deemed too high, activation of GK in the liver increases glucose utilization which in turn lowers blood glucose.